Tecovirimat for Treatment of Monkeypox Virus

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The purpose of this study is to find out if tecovirimat is a safe and effective drug to treat monkeypox (mpox) in combination with standard of care (SOC). Participants will be randomly assigned to receive oral tecovirimat plus SOC or placebo plus SOC for 14 days.
Epistemonikos ID: 1e1c932caeb12ab5a11627239bd988e3d281833c
First added on: Sep 30, 2022